May 2026 in “Mayo Clinic Proceedings” This review article connects key systemic lupus erythematosus pathobiology with current therapies, emphasizes clinical strategies for managing comorbidities, and stresses multidisciplinary care, but it reports no new clinical findings.
45 citations
,
May 2022 in “Biomedicines” This review discusses using human follicular fluid in metabolomic analysis as a diagnostic tool and predictor of success in assisted reproductive technology for PCOS patients, reporting no new results.
12 citations
,
December 2020 in “Comprehensive psychoneuroendocrinology” This study found that progesterone levels were higher and increased significantly throughout pregnancy, contrasting with stable levels in non-pregnant women.
6 citations
,
August 2023 in “European journal of endocrinology” This review discusses the 2023 International Guideline for PCOS assessment and management, highlighting updated evidence-based recommendations and practice points aimed at improving care and health outcomes, but notes that research quality remains generally low to moderate.
4 citations
,
September 2023 in “Nutrients” This review highlights the complex relationship between eating disorders and diabetes, indicating that individuals with diabetes may be at increased risk for eating disorders due to dietary and management demands, which can in turn affect blood sugar control.
1 citations
,
July 2024 in “Frontiers in Pharmacology” In this study, a pregnant woman inadvertently exposed to spironolactone delivered a healthy male infant with normal genitalia, highlighting the need for more research on the safety of spironolactone and new-generation mineralocorticoid receptor antagonists during pregnancy.
1 citations
,
January 2019 in “Journal of the Egyptian Women's Dermatologic Society (Print)” This study observed that while both minoxidil and botanically-derived 5-alpha reductase inhibitors significantly increased hair count and diameter in women with female pattern hair loss, minoxidil was more effective, especially for greater hair diameter increases, but had more troublesome side effects.
December 2024 in “Journal of Clinical Medicine” This review explores the hormonal factors linking polycystic ovary syndrome and psychiatric disorders, such as eating disorders, emphasizing a bidirectional relationship that necessitates a multidisciplinary treatment approach; it reports no new clinical results.
October 2023 in “Journal der Deutschen Dermatologischen Gesellschaft” In this study, a case of rosacea fulminans during pregnancy was successfully treated with a combination of oral azithromycin and prednisone, highlighting this treatment approach for managing similar cases.
1265 citations
,
October 2013 in “The Journal of Clinical Endocrinology and Metabolism” This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.
1 citations
,
May 2017 in “Maturitas” This review discusses the role of physical activity in healthy aging and reports no clinical results; the authors emphasize the need for integrating exercise into daily life and social settings.
April 2023 in “Tikrit Journal of Pharmaceutical Sciences” In this study, researchers assessed the effects of deferasirox in 85 children with ß-thalassemia in Kirkuk and reported that while 55.3% experienced a reduction in serum ferritin, 9.4% had adverse effects, indicating that deferasirox is generally well-tolerated as an iron chelator with modifiable side effects.
February 2018 in “Medical Hypotheses” This article suggests that male pattern hair loss might have historically served as an evolutionary signal for women to choose younger male partners, potentially improving population fitness.
July 2025 in “International Journal of Homoeopathic Sciences” This study suggests that homeopathic treatments may significantly improve menstrual regularity, reduce cystic formations, and enhance the overall quality of life for women with polycystic ovarian disease, indicating its potential as a complementary therapy in gynecological care.
September 2024 in “Brazilian Journal of Case Reports” In this case study, a 62-year-old woman with severe hyperandrogenism underwent a clomiphene test, which suggested an ovarian origin for her condition, leading to the discovery of a Leydig cell tumor after a bilateral oophorectomy.
30 citations
,
January 2016 in “Journal of Pharmaceutical and Biomedical Analysis” This study identified trilauric glyceride and decanoylcarnitine as potential biomarkers for diagnosing PCOS in patients with and without insulin resistance, suggesting significant metabolic alterations in these conditions.
29 citations
,
February 2018 in “Genetics research international” This review summarizes the influence of gene polymorphisms on genetic predisposition to polycystic ovary syndrome, but reports no new experimental or clinical results.
20 citations
,
October 2017 in “Clinical Endocrinology” This article reviews existing knowledge on postmenopausal hyperandrogenism and highlights diagnostic challenges, reporting no new clinical results.
16 citations
,
March 2018 in “Seminars in Oncology” This article compares the immunology of cancer and the placenta and suggests that immunotherapy for pregnant cancer patients could be feasible with careful exploration, though no new clinical results are reported.
2 citations
,
December 2021 in “International journal of Ayurveda and pharma research” This case report describes a 19-year-old girl with PCOS who experienced symptom improvement, including normalized menstruation, after two months of Ayurvedic treatment.
2 citations
,
May 2006 in “Women's Health Medicine” This article provides an overview of ovulation disorders, discussing ovarian, hypothalamic, and endocrine defects but reports no new clinical findings.
1 citations
,
January 2023 in “Bioscience Journal” This study found that combining sorafenib with Platycladus orientalis leaf extract effectively suppressed cervical cancer cell growth by increasing tumor suppressor gene expression and reducing anti-apoptotic gene expression, suggesting a potential rationale for further clinical trials.
January 2019 in “ISGE series” This review discusses the criteria, diagnosis, and treatment options for polycystic ovary syndrome and reports no new clinical results; it highlights the need for further research on causative treatments.
November 2018 in “International Journal of Current Pharmaceutical Research” This review discusses the causes, underlying mechanisms, diagnosis, and treatment strategies for polycystic ovary syndrome but reports no new clinical findings.
September 2018 in “Journal of the American Academy of Dermatology” Elderly patients with CCCA were all African American with low vitamin D, but no iron or zinc deficiencies, and no hormonal imbalances compared to younger patients.
January 2015 in “Side effects of drugs annual” This review discusses various sex hormones and related compounds, including estrogens and anabolic steroids, but reports no new findings; it highlights existing literature from 2014 regarding their use and effects.
January 2025 in “International Journal of Gynaecology Research” This study found that serum cystatin C levels may be elevated in adolescent females with PCOS, suggesting it could serve as a predictive marker for metabolic and cardiovascular issues independent of renal function.
343 citations
,
December 2008 in “Endocrine Reviews” This review discusses the various evidence-based and potential applications of metformin in treating and preventing symptoms and complications associated with polycystic ovary syndrome but reports no new clinical results.
249 citations
,
November 2003 in “Clinical endocrinology” This review discusses the complex etiology of polycystic ovary syndrome (PCOS), highlighting its association with insulin resistance and hyperandrogenism, but reports no clinical findings; the authors suggest further investigation of the pathophysiological mechanisms.
150 citations
,
October 2012 in “Clinical Endocrinology” In this retrospective cohort study, women with polycystic ovary syndrome showed high incidence and age-specific prevalence rates of type 2 diabetes, myocardial infarction, and angina, particularly in those over 65.